GLP
GLP1-SE
GLP-1 Receptor Agonist — Semaglutide
$69Semaglutide is a long-acting GLP-1 receptor agonist featuring an aminoisobutyric acid (Aib) substitution at position 8 and a C18 fatty diacid chain attached via a linker to lysine at position 26. These modifications confer extended duration of action through enhanced albumin binding and DPP-4 resistance in research models.
Extended Half-Life Design
C18 fatty acid acylation enables strong albumin binding, dramatically extending circulating half-life in preclinical pharmacokinetic studies.
DPP-4 Resistance
Aib substitution at position 8 provides resistance to dipeptidyl peptidase-4 enzymatic degradation, a common limitation of native GLP-1.
GLP-1R Selectivity
Maintains selective agonist activity at the GLP-1 receptor for targeted incretin axis research applications.
Semaglutide: A review of the pharmacology and clinical evidence
Comprehensive review of semaglutide's molecular design, receptor pharmacology, and preclinical research data.
| Product Name | GLP1-SE (Semaglutide) |
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 Da |
| Purity | ≥99% (HPLC) |
| Physical Form | White Lyophilized Powder |
| Storage | -20°C, protected from light |
| Certification | Third-party HPLC & MS verified |
| Intended Use | Research and laboratory use only |
